Semi-Annual Statement Of Cash Flows

Cyfuse Biomedical K.K. - Filing #7345925

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2021-12-31
Semi-annual statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-586,187,000 JPY
-471,953,000 JPY
Depreciation
38,122,000 JPY
54,285,000 JPY
Interest expenses
9,774,000 JPY
7,457,000 JPY
Foreign exchange losses (gains)
JPY
4,000 JPY
Decrease (increase) in trade receivables
-3,535,000 JPY
44,108,000 JPY
Decrease (increase) in inventories
-5,646,000 JPY
21,368,000 JPY
Increase (decrease) in trade payables
-1,918,000 JPY
-5,077,000 JPY
Other, net
-16,629,000 JPY
281,000 JPY
Subtotal
-678,354,000 JPY
-400,956,000 JPY
Interest paid
-9,735,000 JPY
-7,453,000 JPY
Income taxes paid
-2,441,000 JPY
-2,009,000 JPY
Net cash provided by (used in) operating activities
-562,296,000 JPY
-403,596,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-19,474,000 JPY
-228,276,000 JPY
Net cash provided by (used in) investing activities
-19,474,000 JPY
-430,674,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
JPY
90,000,000 JPY
Repayments of long-term borrowings
-77,824,000 JPY
-81,420,000 JPY
Proceeds from issuance of shares
22,880,000 JPY
2,328,247,000 JPY
Net cash provided by (used in) financing activities
18,236,000 JPY
2,658,538,000 JPY
Net increase (decrease) in cash and cash equivalents
-563,534,000 JPY
1,824,267,000 JPY
Cash and cash equivalents
2,873,773,000 JPY
3,437,307,000 JPY
1,613,040,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.